Pharmacological foundations of cardio-oncology

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 1, 2010, Pages 2-8

  Minotti, Giorgio ^a   Salvatorelli, Emanuela ^a   Menna, Pierantonio ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROPYRIMIDINE DERIVATIVE; IDARUBICIN; IFOSFAMIDE; LAPATINIB; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PACLITAXEL; RAZOXANE; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CARDIOLOGY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHILDHOOD CANCER; CLINICAL RESEARCH; COMORBIDITY; CORONARY ARTERY SPASM; DIASTOLIC DYSFUNCTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TARGETING; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HODGKIN DISEASE; HUMAN; INCIDENCE; LYMPHOMA; NEOPLASM; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SARCOMA; TESTIS CANCER;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HEART; HUMANS; NEOPLASMS;

EID: 77953734590     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.165860     Document Type: Review

References (40)

1. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, and Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardiooncological prevention. J Natl Cancer Inst 102:14-25.
2. Altena R, de Haas EC, Nuver J, Brouwer CA, van den Berg MP, Smit AJ, Postma A, Sleijfer DT, and Gietema JA (2009) Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer. Br J Cancer 100:1861-1866.
3. Bi W, Drake CJ, and Schwarz JJ (1999) The transcription factor MEF2C-null mouse exhibits complex vascular malformations and reduced cardiac expression of angiopoietin 1 and VEGF. Dev Biol 211:255-267.
4. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, Robison LL, Sklar CA, Stovall M, and Bhatia S (2008) Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112:2789-2795.
5. Cairo G, Recalcati S, Pietrangelo A, and Minotti G (2002) The iron regulatory proteins: targets of free radicals and modulators of oxidative damage. Free Rad Biol Med 32:1237-1243.
6. Cardinale D (1996) [A new frontier: cardio-oncology]. Cardiologia 41:887-891.
7. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, and Cipolla CM (2006) Prevention of high-dose chemotherapy- induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474-2481.
8. Carver JR, Schuster SJ, and Glick JH (2008) Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities. J Clin Oncol 26:3122-3124.
9. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ, and ASCO Cancer Survivorship Expert Panel (2007) American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 25:3991-4008.
10. Cheng H and Force T (2010) Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 106:21-34.
11. De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, Ferreira-Martins J, Zheng H, Hosoda T, Rota M, et al. (2010) Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 121:276-292.
12. De Bruin ML, Dorresteijn LD, van't Veer MB, Krol AD, van der Pal HJ, Kappelle AC, Boogerd W, Aleman BM, and van Leeuwen FE (2009) Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 101:928-937.
13. De Keulenaer GW, Doggen K, and Lemmens K (2010) The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 106:35-46.
14. Doggen K, Ray L, Mathieu M, Mc Entee K, Lemmens K, and De Keulenaer GW (2009) Ventricular ErbB2/ErbB4 activation and downstream signaling in pacinginduced heart failure. J Mol Cell Cardiol 46:33-38.
15. Ewer MS and Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900-2902.
16. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, and Sawyer DB (2008) Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26:3777-3784.
17. Hasinoff BB (2010) The B. B. cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol Appl Pharmacol 244:190-195.
18. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, Dumontet C, Thieblemont C, Arnaud P, et al. (2004) Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22:1864-1871.
19. Herman EH, el-Hage AN, Ferrans VJ, and Ardalan B (1985) Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol Appl Pharmacol 78:202-214.
20. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, and Mackey JR (2007) Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 50:1435-1441.
21. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, and Ergin A (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258-2262.
22. Kamp O, Metra M, De Keulenaer GW, Pieske B, Conraads V, Zamorano J, Huysse L, Vardas PE, Böhm M, and Dei Cas L (2010) Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clin Res Cardiol 99:75-82.
23. Lebrecht D and Walker UA (2007) Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol 7:108-113.
24. Lee KF, Simon H, Chen H, Bates B, Hung MC, and Hauser C (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394-398.
25. Lemmens K, Segers VF, Demolder M, and De Keulenaer GW (2006) Role of neuregulin- 1/ERBB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem 28:19469-19477.
26. Menna P, Salvatorelli E, and Minotti G (2008) Cardiotoxicity of antitumor drugs. Chem Res Toxicol 21:978-989.
27. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
28. Minotti G, Recalcati S, Mordente A, Liberi G, Calafiore AM, Mancuso C, Preziosi P, and Cairo G (1998) The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J 12:541-552.
29. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, et al. (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. Br Med J 339:34.
30. Pegram M and Ngo D (2006) Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study. Adv Drug Deliv Rev 58:723-734.
31. Peng B, English MW, Boddy AV, Price L, Wyllie R, Pearson AD, Tilby MJ, and Newell DR (1997) Cisplatin pharmacokinetics in children with cancer. Eur J Cancer 33:1823-1828.
32. Pentassuglia L, Graf M, Lane H, Kuramochi Y, Cote G, Timolati F, Sawyer DB, Zuppinger C, and Suter TM (2009) Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res 315:1302-1312.
33. Salvatorelli E, Guarnieri S, Menna P, Liberi G, Calafiore AM, Mariggiò MA, Mordente A, Gianni L, and Minotti G (2006) Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. J Biol Chem 281:10990-11001.
34. Salvatorelli E, Menna P, Gianni L, and Minotti G (2007) Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies. J Pharmacol Exp Ther 320:790-800.
35. Salvatorelli E, Menna P, Lusini M, Covino E, and Minotti G (2009) Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart. J Pharmacol Exp Ther 329:175-184.
36. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, and Schmidinger H (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204-5212.
37. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, et al. (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859-3865.
38. Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister A, Radford JA, Rohatiner AZ, and Linch DC (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99:206-214.
39. van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, Schimmel EC, Aleman BM, and van Leeuwen FE (2006) Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24:467-475.
40. Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, and Mohler ER (2008) Cardiovascular risk in long-term survivors of testicular cancer. Cancer 112:1949-1953.